Evidence & regulatory context
- Mechanism
- Drug-class entry: no agent named in the source abstract, so resolved=false and no ChEMBL lookup was possible. FLAGGED: n_trials deliberately left 0. The 496 query hits were dominated by cytotoxic topotecan oncology regimens (topotecan has HIF-1alpha translation-inhibitory activity but is not trialled for that purpose) and by HIF-2alpha agents such as PT2385 and belzutifan, a different isoform; none was recorded as HIF-1alpha-inhibitor translation evidence.
- Target
- Not recorded
- Injury models
- Haemorrhage/shock
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatHaemorrhage/shockUnspecifiedSprague-DawleyMale
Model: Trauma and haemorrhagic shock induced acute lung injury, with mesenteric lymph from trauma/haemorrhagic shock applied to cells in vitro
HIF-1alpha was activated and succinate dehydrogenase inhibited in the lung during trauma and haemorrhagic shock induced acute lung injury. Pharmacological inhibition of HIF-1alpha attenuated lung inflammation and pulmonary oedema, indicating that HIF-1alpha activation is detrimental in this model.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
